SPONSORSHIP & SPONSORS
Please find on overview of the sponsors for the 2024 Conference here:
Gold Sponsors
Company description
Vancouver-based Acuitas Therapeutics is a globally recognized private biotechnology company specializing in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles (LNP).
Company description
Aldevron is a premier manufacturing partner, producing high-quality plasmid DNA, RNA, proteins, and other key components for the development of vaccines, gene and cell therapies, immunotherapies, and other treatments. Headquartered in Fargo, North Dakota, and as a part of the Danaher Corporation (NYSE: DHR) family of global science and technology companies, Aldevron supports thousands of scientists who are developing revolutionary, lifesaving treatments for millions of people.
Company description
About BioNTech
Biopharmaceutical New Technologies (BioNTech) is a global next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. BioNTech exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor (CAR) T cells, several protein-based therapeutics, including bispecific immune checkpoint modulators, targeted cancer antibodies and antibody-drug conjugate (ADC) therapeutics, as well as small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. For more information, please visit www.BioNTech.com.
Company description
Certest Pharma specializes in advanced lipid nanoparticle technology, focusing on the development of effective and targeted LNPs for next-generation medicines. Our licensable technology includes top-performing proprietary ionizable lipids (our main asset) and optimized LNP formulations with excellent performance in vivo and which can induce extrahepatic delivery.
We also offer design, production, and analysis of oligonucleotides in GMP-like quality.
Certest Pharma provides cutting-edge solutions with different payloads for RNA therapies and collaborate with various partners to enhance global healthcare.
Company description
CureVac is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology for application in human medicine. In more than two decades of developing, optimizing, and manufacturing this versatile biological molecule for medical purposes, CureVac has introduced and refined key underlying technologies that were essential to the production of mRNA vaccines against COVID-19, and is currently laying the groundwork for application of mRNA in new therapeutic areas of major unmet need. CureVac is leveraging mRNA technology, combined with advanced omics and computational tools, to design and develop off-the-shelf and personalized cancer vaccine product candidates. It also develops programs in prophylactic vaccines and in treatments that enable the human body to produce its own therapeutic proteins. Headquartered in Tübingen, Germany, CureVac also operates sites in the Netherlands, Belgium, Switzerland, and the U.S. Further information can be found at www.curevac.com.
Company description
With a rich heritage dating back hundreds of years, Cytiva brings a wealth of technical expertise and talent, a broad and deep portfolio, and exceptional service help researchers and biopharma advance therapeutics at every stage from discovery to delivery.
We supply the tools and support our customers need to work better, faster, and safer, leading to the delivery of transformative medicines to patients. Our combined portfolio includes well-recognized names such as Allegro™, Supor™, iCELLis™, and Kleenpak™, in addition to ÄKTA™, Amersham™, Biacore™, FlexFactory™, HyClone™, MabSelect™, Sefia™, Whatman™, and Xcellerex™. Visit cytiva.com to learn more.
Company description
FUJIFILM Corporation is transforming into a healthcare company through leveraging fine-chemical technologies cultivated in photo-films’ manufacturing, such as organic-chemistry and nanotechnologies. Based on these assets, we have started one-stop CDMO service from bench top formulation research to GMP manufacturing for lipid nanoparticles utilizing Fujifilm’s proprietary ionizable lipids.
Company description
Moderna is a leader in the creation of the field of mRNA medicine. Through the advancement of mRNA technology, Moderna is reimagining how medicines are made and transforming how we treat and prevent disease for everyone. By working at the intersection of science, technology and health for more than a decade, the company has developed medicines at unprecedented speed and efficiency, including one of the earliest and most effective COVID-19 vaccines.
Moderna’s mRNA platform has enabled the development of therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. With a unique culture and a global team driven by the Moderna values and mindsets to responsibly change the future of human health, Moderna strives to deliver the greatest possible impact to people through mRNA medicines. For more information about Moderna, please visit modernatx.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.
Company description
Polymun Scientific GmbH
is a private Austrian company, located in Klosterneuburg, offering contract development and manufacturing of biopharmaceuticals as well as development and production of LNP and liposomal formulations. Its patented liposome/LNP technology allows efficient manufacturing of constantly high quality in small and large scale.
Over the last 15 years, Polymun has guided LNP and liposomal formulations into clinical trials, amongst them DNA and different kinds of RNA formulations. A prominent example is Polymun’s contribution to the BioNTech/Pfizer Covid-19 vaccine. Here the team at Polymun Scientific has significantly contributed to the 1st successful mRNA vaccine Comirnaty by optimizing and up-scaling the LNP process as well as by supporting clinical and early market supply.
Polymun is an FDA- and EMA-inspected manufacturer conducting several own R&D projects. For more information, please visit www.polymun.com
Company description
Quantoom Biosciences is leading the revolution in mRNA-based vaccines and therapeutics by offering turnkey solutions for mRNA-LNP manufacturing. Its cutting-edge Ntensify™ technology enables the production and purification of mRNA through a fully integrated, scalable system that combines processes, equipment, reagent mixes, and disposables. This solution supports the entire spectrum of mRNA production, from R&D to commercial manufacturing. Launched in 2023, Ntensify™ has already been widely adopted across multiple continents, showcasing its global appeal. Quantoom Biosciences is also developing the Ncapsulate™ technology for mRNA-LNP formulation and purification, aiming to significantly increase the accessibility and affordability of mRNA-based drugs. Located in Belgium, Quantoom Biosciences thrives in a dynamic biotech ecosystem, driving innovation in mRNA production to make life-changing therapies available to everyone, everywhere.
Company description
From vaccines and immunotherapies to protein replacement and cell reprogramming, interest in mRNA manufacturing has surged. Decades before the pandemic, Roche CustomBiotech has supplied nucleotides and enzymes for mRNA production. We work with many pioneering mRNA companies to develop and manufacture needed raw material solutions. In collaboration with therapeutic manufacturers, our portfolio has evolved to meet the changing needs of the mRNA field. Always abreast with market developments, Roche CustomBiotech enables a new generation of mRNA therapeutics. Our guiding tenet is to minimize variation of products built on our raw materials by ensuring best quality, high performance within narrow tolerances, and reliable delivery.
Remaining at the front of this fast-paced therapeutic space hinges not only on ideas and implementation, but also on speed and quality. Your expertise is coming up with the idea and the implementation; as a long-standing global supplier, Roche CustomBiotech’s expertise in raw materials can help you accelerate development and ensure high quality mRNA. We help you strengthen your supply chain, ease transfers to manufacturing, secure continuous production, and create consistently high-quality products.
Company description
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Sanofi’s mRNA Center of Excellence (CoE) pursues the development of new mRNA vaccine candidates to address the long-standing challenges in cancer, immune-mediated diseases, and rare diseases, focusing on thermostability and tolerability.
Company description
TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed, to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders, to enabling future pandemic response plans.
Company description
From vaccines and immunotherapies to protein replacement and cell reprogramming, interest in mRNA manufacturing has surged. Decades before the pandemic, Roche CustomBiotech has supplied nucleotides and enzymes for mRNA production. We work with many pioneering mRNA companies to develop and manufacture needed raw material solutions. In collaboration with therapeutic manufacturers, our portfolio has evolved to meet the changing needs of the mRNA field. Always abreast with market developments, Roche CustomBiotech enables a new generation of mRNA therapeutics. Our guiding tenet is to minimize variation of products built on our raw materials by ensuring best quality, high performance within narrow tolerances, and reliable delivery.
Remaining at the front of this fast-paced therapeutic space hinges not only on ideas and implementation, but also on speed and quality. Your expertise is coming up with the idea and the implementation; as a long-standing global supplier, Roche CustomBiotech’s expertise in raw materials can help you accelerate development and ensure high quality mRNA. We help you strengthen your supply chain, ease transfers to manufacturing, secure continuous production, and create consistently high-quality products.
Company description
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.
Sanofi’s mRNA Center of Excellence (CoE) pursues the development of new mRNA vaccine candidates to address the long-standing challenges in cancer, immune-mediated diseases, and rare diseases, focusing on thermostability and tolerability.
Silver Sponsors
Company description
FDX, based in Berlin, offers its proprietary and patented FDmiX Technology for the formulation of nano based drug delivery systems.
Based on its OsciJet technology FDX is able to improve and optimize fluid dynamic processes through the introduction of dynamic movement. By integrating the OsciJet technology into a mixing device, FDX created the FDmiX platform. The FDmiX offers extremely fast and homogenous mixing at all production scales.
The FDmiX platform leads, depending on application, to:
• more homogeneous nanoparticles with PDI<0.1 (depending on formulation)
• smaller nanoparticles
• hassle-free scale up without parallelization
• one platform for all production scales
Company description
At Lonza, we enable a healthier world by supporting our healthcare customers on the path to commercialization. Working across five continents, our global community of around 18,000 colleagues helps pharmaceutical, biotech and nutrition companies to bring their treatments to market.
United by our vision to bring any therapy to life, we support our customers with a combination of technological insight, world-class manufacturing, scientific expertise, process excellence and innovation. Our work enables our customers to develop and commercialize their therapeutic discoveries, allowing their patients to benefit from life-saving and life-enhancing treatments.
Company description
MilliporeSigma is the U.S. and Canada Life Science business of Merck KGaA, Darmstadt, Germany. We provide solutions to help you overcome your mRNA manufacturing and LNP formulation challenges. Our integrated CTDMO capabilities include the development and manufacturing of custom mRNAs, synthetic lipids, lipid nanoparticle (LNP) formulation and fill and finish. Discover how our capabilities, technical expertise and regulatory know-how can help you deliver and scale up your mRNA-based vaccines and therapeutics, accelerate time to market and mitigate risks.
Company description
Our Purpose
We’re in relentless pursuit of breakthroughs that change patients’ lives. We innovate every day to make the world a healthier place. It was Charles Pfizer’s vision at the beginning and it holds true today.
Our Responsibility
Our unique resources allow us to do more for people. Using our global presence and scale, we’re able to make a difference in local communities and the world around us.
Health Policies
We advance medical innovation and distribute medicines that might not otherwise be available to underserved communities.
Company description
ReciBioPharm, a division of Recipharm, is a contract development and manufacturing organization (CDMO) specifically established to focus on serving companies seeking to develop and commercialize advanced therapy medicinal products (ATMPs). ReciBioPharm’s specialized CDMO capabilities include pre-clinical to clinical and commercial development and manufacture for new biological modalities encompassing technologies based on live viruses and viral vectors, live-microbial biopharmaceutical products, nucleic acid-based mRNA and plasmid DNA production. Led by a management team and technical experts with a proven track record in both process development and contract manufacturing, ReciBioPharm offers the knowledge and resources necessary to help customers develop and manufacture promising new therapies to meet the needs of patients across the world.
Company description
Founded in South Korea in 1924, Samyang is a conglomerate company that operates across various business sectors, including Biopharmaceuticals, Food, Chemicals, Packaging and Cosmetics.
Samyang Biopharm USA, Inc. (“SYBUSA”) was founded in 2018, headquartered in One Kendall Square, Cambridge MA. Playing a vital role as a business hub in the United States, SYBUSA focuses on building partnerships with pharmaceutical companies for Samyang’s nucleic acid drug delivery system in the United States.
Over the last decades, Samyang’s long dedication in developing drug delivery systems based on biodegradable polymers and polymeric-micelle formulation technology had led to successful commercialization of modified anti-cancer generics and medical devices, receiving global recognition for their superior quality and safety.
Currently, our strong focus is on developing drug delivery systems, called SENS™ (Stability Enhanced Nano Shell), for tissue-selective delivery of nucleic acid therapeutics. SENS™ is uniquely composed of biodegradable polymer component and newly discovered cationic lipids. By varying the compositions and fine-tuning the mixing processes, SENS™ formulations are optimized to deliver mRNA to selective tissue (spleen, lung, and liver etc.) with superior toxicity profiles, allowing for repeat dosing procedures.
NanoReady, one of our proprietary SENS™ libraries, is characterized by its ready-to-use format. As a pre-made nanoparticle system, it can simply be combined with mRNA molecule before use in patient, which allows streamlining the process development, reducing the time-to-patient, and making personalized cancer vaccine possible. Through actively collaborating with global partners, we have been expanding our SENS™ libraries applied to various mRNA therapeutics, including prophylactic, therapeutic cancer vaccines, protein replacement, gene editing medicines, and more.
Bronze Sponsors
Company description
Anemocyte, a Biotech Manufacturing Organization based in Italy, offers development and manufacturing services of:
– pDNA – Plasmids for Viral Vector and RNA manufacturing;
– mRNA – mRNA manufacturing for Vaccines and Therapies.
Our experience: > 20 years of manufacturing innovative Therapies.
Company description
ARCALIS is a CDMO specialized in mRNA vaccines and therapeutics, contributing to prolonging life expectancy, and improving quality of life by providing innovative mRNA development and manufacturing. ARCALIS was jointly established by Axcelead, the first drug discovery platform company in Japan, and Arcturus Therapeutics, a US-based global late-stage clinical mRNA medicine company. ARCALIS provides seamless services from drug discovery to large-scale GMP compliant manufacturing for mRNA therapeutics and vaccines to pharmaceutical companies and academia. Our services are based on the transferred technology and innovative knowledge from Arcturus in terms of mRNA manufacturing and quality control. ARCALIS provides cutting-edge services such as identifying and optimizing mRNA nucleotide sequences for efficient target protein expression with precise quality control. Furthermore, our newly established commercial plant, which capacity to synthesis mRNA is up to 5 kg per year, is capable to produce high-quality mRNAs of interest.
Company description
Areterna LLC was founded in 2023 as a wholly-owned subsidiary of Synthgene Biotechnology Co., Ltd. to serve customers in the US and Europe.
Synthgene is a company that provides materials and services to support mRNA and oligonucleotide manufacturing. Founded in 2018 by a group of passionate nucleic acid chemists, the goal of the company is to debottleneck the raw material supply and develop innovative solutions to support customers in the industry. The company has a robust quality system and ISO9001 certification to support cGMP manufacturing of mRNA raw materials that include NTPs, modified NTPs and cap analogs. For the GMP raw materials, Drug Master Files have been filed with FDA. In addition, Synthgene offers analytical development service and mRNA-related impurity standards and detection kits, LNP screening service, IVT process development and IVT kits for mRNA research. For solid-phase DNA and RNA synthesis, Synthgene offers high quality phosphoramidites to support cGMP oligo manufacturing. With over 200 scientists in R&D and AI-assisted discovery platform, Synthgene will continue to bring new products to the market.
Company description
BIOVECTRA is a global biotech and pharmaceutical CDMO that specializes in clinical-to-commercial scale production capabilities for biologics, small molecules, bioreagents, pDNA and mRNA manufacturing, and fill/finish. Flexibility, creativity, process optimization, and compliance are at the heart of our method. With more than 50 years of experience, over 630 employees, and cGMP facilities in Prince Edward Island and Nova Scotia, Canada we assure our programs advance on time and with the highest quality outcomes. Learn more about BIOVECTRA today!
Company description
CordenPharma is a CDMO partner supporting biotech and pharma innovators of complex modalities in the advancement of their drug development lifecycle. Harnessing the collective expertise of the teams across its globally integrated facility network, CordenPharma provides bespoke outsourcing services spanning the complete supply chain, from early clinical-phase development to commercialization.
With scientific expertise and partnership at its core, CordenPharma provides customers high-value, end-to-end services with a strategic focus on Peptides, Oligonucleotides, customized Lipid Excipients, Lipid NanoParticles (LNPs), sterile Injectables, and the extensive supply of Small Molecules (both Highly Potent and Regular Potency).
The CordenPharma Group is comprised of 11 facilities across Europe and North America. In the 2023 financial year, the organization generated sales of €880 million and had over 3,000 employees.
Company description
About Croda’s Pharma business – www.crodapharma.com
Croda’s Pharma business is a leading partner for the development of excipients and the supply of high purity materials for pharmaceutical formulations, committed to enabling the next generation of drug delivery systems. The business is focused on empowering biologics drug delivery, through its adjuvant systems, small molecule, protein, and nucleic acid, delivery platforms.
About Avanti Research – www.avantiresearch.com
Avanti Research (formerly Avanti Polar Lipids) was founded in 1967 to meet the demand for highly purified lipids in scientific research. Over the decades, these lipids have built a world-renowned reputation. Now a part of the Croda family, the Avanti Research brand leads the way with the highly purified lipids, ingredients and services for pharmaceutical and fundamental research, and diagnostics. With a catalogue boasting over 2,000 lipids, Avanti Research also offers custom lipid synthesis and formulation development.
Company description
Curapath, is a global CDMO specialized in the tailored design, development, and GMP manufacturing of cutting-edge polymer and lipid-based drug delivery systems. Our customers benefit from our unique expertise, operational excellence and technical solutions in polymer (PNPs) and lipid nanoparticles (LNPs) along with their essential components.
In addition, we have extensive experience in drug conjugation and crosslinking, to increase stability, reduce toxicity, and enhance bioactivity.
At Curapath, we stand as your partner from discovery stages to commercial GMP scale-up. With our dedicated support, expertise, and state of the art manufacturing capabilities, we assure you a guaranteed path for your drug to navigate through clinical development and reach commercialization seamlessly.
Company description
Eclipsebio develops first-in-class technologies, analyses, and platforms for the development of tomorrow’s RNA-based and RNA-targeting therapies. With our extensive experience in supporting early-stage basic research to evaluating preclinical vaccines and gene therapies, we provide unparalleled support for obtaining deep insights into RNA and therapeutic biology. We offer our solutions as end-to-end partnerships, including custom assay development, for biopharma and biotech companies and as a la carte services.
Company description
Evonik’s Health Care business line is a fully integrated solutions provider for advanced drug delivery and can support you at any stage of the drug development process, including manufacturing of pharmaceutical excipients, developing innovative formulations, as well as the production of clinical drug product through commercial quantities.
As one of the world’s leading specialty chemicals, Evonik focus on more specialty businesses, customer-orientated innovative prowess and a trustful and performance-oriented corporate culture. The company is active in more than 100 countries around the world and generated sales of €15.3 billion and an operating profit (adjusted EBITDA) of €1.66 billion in 2023.
Company description
GSK is one of the world’s leading research-based healthcare companies. GSK places R&D at the heart of innovation, harnessing immune science, human genetics, and advanced technologies to deliver new and specialty products. Our science-led vaccines business spans discovery to late-phase development. We continuously strive to accelerate vaccine development and strengthen supply performance. To deliver greater positive impact for patients around the world, strategic partnerships are of vital importance.
If you like to learn more, please feel free to contact us at vaccinespartnering@gsk.com or visit www.gsk.com.
Company description
Hanmi Fine Chemical has developed a novel 5’ cap analog series which could be applied to co-transcriptional mRNA and saRNA synthesis. The current HanmiCap® series consists of two AG cap analogs (HC07, HC13) and two AU cap analogs (HC11, HC20). While HC07 showed comparable results against the commercial cap, HC13 and HC11 demonstrated significantly higher translation levels in vivo. HC13 in particular, is demonstrating significantly reduced dsRNA (double-stranded RNA) levels which is an essential factor for therapeutic development in the mRNA field. Hanmi Fine Chemical is delighted to present HanmiCap®, ensuring exceptional outcomes in the development of your mRNA therapeutics.
Company description
Found in 1998, Hongene is an end-to-end partner for specialist nucleic acid manufacturing, offering a wide range of products to meet the needs of the life sciences industry. From standard raw material building blocks to complex oligonucleotides and mRNA, Hongene consistently delivers with exceptional quality and value. Our world-leading manufacturing capacity of phosphoramidites is 58 tons and 54,000 liters for NTP per year, sufficient to support customers from small-scale to commercial production.
Company description
Hzymes Biotechnology has developed hundreds of raw materials related to biopharmaceutical and vaccine production based on the technology platforms of enzyme gene mining and performance characterization, enzyme molecule optimization and modification, high throughput screening of enzyme genes, organic synthesis, synthetic biology, and R&D and preparation of antigens and antibodies, etc. Hzymes Biotechnology can provide customers with a full set of enzyme raw materials required for the production of mRNA drugs and vaccines, as well as various types of T7 RNA polymerase mutants, chemical substrates, cap analogs, etc.We also have a pharmaceutical-grade special enzyme production system with a super-large production scale and super-high equipment standards. It has provided products and services to more than 300 domestic manufacturers of bio-pharmaceuticals, vaccine preparations, and in vitro diagnostic reagents. Meanwhile, our products have been exported to 25 overseas countries and regions.
Company description
For 50 years, New England Biolabs (NEB) has pioneered the discovery and production of innovative products tailored for molecular biology research. Our commitment to scientific discovery is evident in all that we do, including our ever-expanding product portfolio, investment in our basic and applied research program, and support of customers’ research in academia and industry, including cutting-edge technologies for use in molecular diagnostics and nucleic-acid vaccines development. Guided by our founding principles, NEB proactively invests in efforts to improve the well-being of our employees, surrounding communities, as well as the future of our planet. NEB remains a privately held company with global reach, supported by our headquarters in Ipswich, MA, USA, subsidiary offices in 10 countries, and over 60 distribution partners around the world. For more information about New England Biolabs, visit www.neb.com.
NEB® and NEW ENGLAND BIOLABS® are registered trademarks of New England Biolabs, Inc.
Company description
NOF CORPORATION, the leading commercial supplier of drug delivery products through R&D to commercial scale, provides activated PEGs for protein modification, single molecular PEGs for ADCs, Polysorbate 80 for formulation of biological medicines, PEG lipids and ionizable lipids for lipid nanoparticle (LNP) formulations. NOF’s lipid nanoparticle platform for nucleic acid delivery composed of COASOMEⓇ SS Series, a novel biodegradable ionizable lipid, demonstrates superior endosomal escape and provides high protein expression with extremely low systemic toxicity. The platform can be applied to gene delivery, gene editing, nucleic acid vaccine and in vitro transfection. It is capable of encapsulating pDNA, siRNA and mRNA, and delivering these to various organs and tissues. NOF LNP platform is becoming adopted in clinical planning by NOF collaborators.
Company description
Northern RNA
MANUFACTURING A BETTER FUTURE
We are a Canadian contract development and manufacturing organization (CDMO) specializing in the production of nucleic acid and lipid products that support life-enabling work. We strive towards this daily by developing and deploying our state-of-the-art bioprocessing and chemical process technologies, using proprietary manufacturing and analytical approaches, employing a highly skilled workforce, and partnering with an excellent and extensive network of relationships and collaborations. We support our customers by providing scalable manufacturing capacity and help them accelerate innovation in bringing their products from benchtop to bedside or field.
Company description
Nature’s Toolbox, Inc. (NTx) has re-imagined how biomanufacturing can be done, using a proprietary, easily scalable, continuous flow, cell-free system that fits on a benchtop or in a small isolator glovebox, with the goal of democratizing the production of RNA and proteins, to enable global access to the next generation of vaccines and therapeutics.
Using our proprietary enzymes and bioreactor systems, we can make RNA (including mRNA, saRNA, etc.) in a fraction of the time and cost, simultaneously decreasing purification and other associated costs using traditional bioprocessing methods. The technology systems are also efficiently tunable, making them useful to address product updates that may be needed (e.g. to address new virus variants, like in COVID). The technology enables R&D and clinical production of next-generation therapeutic modalities, like self-amplifying RNA, which are incredibly difficult to manufacture using commercially available equipment and processes.
Company description
Phosphorex is a leading provider of drug delivery technologies and solutions. By harnessing the potential of microspheres and nanoparticles for drug delivery, Phosphorex offers tailored solutions and enabling technologies to optimize a drug’s release rate, targeting ability, bioavailability, and deliverability, with the goal of achieving desired therapeutic effects while reducing adverse clinical outcomes. Phosphorex supports pharmaceutical and biotech companies through all phases of their development, from proof of concept to clinical studies and will offer cGMP manufacturing services in 2025. Phosphorex’s mission is to help our partners solve complex problems and develop successful drugs to help patients. Additional information about Phosphorex is available at www.phosphorex.com or follow us on LinkedIn.
With our expertise and innovative technologies, we excel in encapsulating drugs into microspheres or nanoparticles, enabling targeted delivery, protection of therapeutic agents, controlled release, and improved bioavailability. From proof-of-concept to clinical studies, our integrated solution supports all phases of formulation development.
Our team of technical experts brings extensive experience in various areas, including:
– Lipid Nanoparticles (LNPs) for Nucleic Acid Delivery
– Polymeric Nanoparticles (PNPs) for Targeted Delivery
– Polymeric Microspheres (PMPs) for Sustained-release Delivery
Phosphorex is at the forefront of harnessing the immense potential of microspheres and nanoparticles to revolutionize drug delivery. We provide a comprehensive range of customizable drug delivery solutions, catering to diverse applications. From formulation development to clinical trials, we work closely with clients and collaborators to bring innovative therapies to life.
When working with us, our team of experts offer:
– Customizable Solutions: We understand the unique requirements of each application and tailor our drug delivery systems, accordingly, ensuring precision and effectiveness
– Collaborative Approach: We foster close partnerships with our clients and collaborators, working hand-in-hand throughout the entire drug formulation & development journey
– Seamless Transitions: From formulation development to clinical trials, our integrated approach ensures a smooth and efficient progression, saving valuable time and resources
– Innovative Technologies: With the use of advanced systems & technologies and our expertise in microspheres and nanoparticles allows us to develop advanced drug delivery solutions that optimize therapeutic outcomes
Phosphorex offers the following services:
– Formulation Feasibility & Optimization
– Process Development & Scale Up
– Pre-clinical Batch
– cGMP Manufacturing (Coming in 2025)
– Supporting Analytical Services
Our Payload Expertise Includes:
– Nucleic Acid Payloads: DNA, mRNA, siRNA, and antisense oligonucleotides (ASO) find their ideal carriers in lipid nanoparticles (LNPs), maximizing their therapeutic potential.
– Small Molecules, Peptides, and Proteins: Biodegradable polymers form the foundation for our microspheres and nanoparticles, effectively encapsulating these payloads to enhance their performance.
– Other Formulations: Explore our wide array of formulations, including liposomes, micelles, nanocrystals, hydrogels, and their combinations, boosting the efficacy of active ingredients.
Our Drug Carrier Expertise Includes:
– Lipid Nanoparticles
– Liposomes
– Polymeric Nanoparticles
– Polymeric Microspheres
– Micelles
– Lipid-polymer Hybrid
– Polyplexes
At Phosphorex, we are committed to pushing the boundaries of drug delivery, delivering superior solutions, and driving the success of our clients. Partner with us to unlock the full potential of your pharmaceutical innovations. Contact us at bd@phosphorex.com today.
Company description
We are a Dutch mRNA technology provider and mRNA manufacturer (R&D- and GMP-grade) supporting over 250 customers worldwide in the design, synthesis, of high-quality mRNA and LNP formulation for various applications including vaccination and therapeutic use. We offer a range of services that enable mRNA therapy pioneers to develop the medicines of the future: from mRNA design, to R&D- and GMP-grade manufacturing of (LNP-formulated) mRNA, and contract research services; our one-stop-shop has you covered.
In addition, our licensable technologies on mRNA design, manufacturing processes and LNP formulations provide our customers a head start in the competitive marketplace.
Finally, RIBOPRO is developing a proprietary flow-based, fully automated production and GMP compliant system, delivering an event greater scaling flexibility, combined with ultra-fast production timelines.
Company description
Here’s the deal. We’re all about helping biologics and gene therapy researchers break free from tools that just don’t cut it. Unleashing problem-tackling solutions that make a huge difference in the real science they do every day. That’s our mantra, our promise and we own it.
Company description
Wacker Biotech offers mRNA production across the full manufacturing chain, from plasmid DNA (pDNA) to mRNA to LNP formulation, for vaccines and advanced gene therapies. Offerings include diverse solutions ranging from pDNA supply using our PLASMITEC® platform, to process development, transfer of mRNA-based processes, and GMP manufacturing for clinical and commercial supply. Additionally, customers benefit from a broad spectrum of LNP formulations for their mRNA-based product.
In June 2024, we completed construction and opened a state-of-the-art mRNA competence center in Halle, Germany, which effectively triples our mRNA production capacity. This complements existing capabilities at our global GMP facilities in Amsterdam, Halle and San Diego. Also complementing these sites is a dedicated R&D center in Munich, Germany with scientific experts leading innovations in pDNA manufacturing, mRNA production, LNP formulation, and analytical development.
Wacker Biotech is a wholly owned subsidiary of 110-year-old Wacker Chemie AG and also specializes in producing recombinant proteins based on microbial systems and Live Biotherapeutic Products. For more information, visit: wacker.com/biologics.
Item #1
Item #1
Item #1
Item #1
Item #1
Item #1
Basic Sponsors
Company description
Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (sa-mRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. Arcturus developed KOSTAIVE®, the first self-amplifying messenger RNA (sa-mRNA) COVID vaccine in the world to be approved. Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase (OTC) deficiency and cystic fibrosis (CF), along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (over 400 patents and patent applications in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.
Company description
We are No1 CDMO servicer in Japan, over 600 mRNA production.
“Accelerate your R&D with our high-quality mRNA manufacturing services!”
We are engaged in the Induced pluripotent stem cell (iPSC) business and the mRNA CDMO business, based on our transcription factor-based Quick-Tissue (TM) technology and mRNA manufacturing know-how. In the mRNA CDMO business, we propose the best solutions for your challenges such as the designing, production and/or purification. In addition, we can deliver both research grade and clinical grade at our cGMP-compliant facilities in Japan.
Enovo Life Sciences
Enovo Life Sciences is an institutionally capitalized life sciences platform, focused on partnering with innovative businesses serving the biologics and advanced therapies end markets.
Backed by Warburg Pincus, a leading global growth investor, Enovo Life Sciences will provide companies with capital, sector expertise and a global network to further accelerate innovation and meet the needs of customers and patients worldwide.
Website: www.enovolifesciences.com
Company description
Exothera is a contract, development, and manufacturing organization (CDMO) dedicated to viral vector and nucleic acids production. As a technology-driven company, Exothera provides best-in-class bioprocessing expertise that capitalizes on the best and most innovative manufacturing technologies. The company delivers accelerated discovery services as well as process development/optimization to rapidly reach GMP clinical and commercial production of vaccines, viral vectors, oncolytic viruses, and nucleic acids. For more information, visit www.exothera.world.
Company description
At InsideTX, we are revolutionizing nanoparticle manufacturing, to unlock the full potential of RNA-LNP therapeutics and nanomedicines.
At the convergence of microfluidics and biotechnology, we strive to provide laboratories, biotech, and pharma companies with the ultimate nanoparticle synthesis capabilities by solving three of the biggest challenges of the RNA-LNP revolution: Easing screeening, ensuring seamless scalability all along the development process and allowing for continuous production GMP Grade.
Leveraging our patented technology, our complementary team is developping the only end-to-end nanoparticle synthesis platform that accelerates your screening to production time while improving your probability of success.
In practices, our system allow for easy manufacturing of most lipidic or polymeric nanoparticles (liposomes, LNP, solid lipid nanoparticles, PLGAs…) using the same system all along your drug development process – from your screening stage at µL scale to your continuous production at 10s of L scale – while ensuring ultimate nanoparticle characteristics control at every step of the process.
Our first nanoparticle formulation system TAMARA meets these challenges head-on, offering a comprehensive, all-in-one R&D platform that supports every phase of preclinical development, from initial screening to in-vivo studies. With zero dead volumes and reusable microfluidic chips, TAMARA is the ultimate solution for RNA-LNP or nanomedicine development.
But don’t just take our word for it—our users say it best: “I’m absolutely blown away by how user-friendly, efficient, and straightforward this system is!”
Company description
Kudo Biotechnology, Inc (Kudo Bio) is a leading global contract development and manufacturing organization (CDMO), providing world-class, end-to-end mRNA manufacturing solutions all under one roof, as well as commercial fill-finish. Kudo Bio is headquartered in the US and has state-of-the-art facilities including a Process Science Center of Excellence in Needham, Massachusetts, a clinical GMP manufacturing facility and MSAT laboratories in Shanghai, with additional presence in Singapore. Our GMP manufacturing facility spans over 57,000 sqf, designed in accordance with cGMP and global regulatory guidelines, and our production lines cater for preclinical through Phase 3 and commercial. We also offer Fill & Finish, Testing & Release, and Supply Chain Management, and for mRNA and LNP manufacturing we also offer Process and Analytical Development and Technology Transfer. Kudo Bio has a robust quality management system to ensure the highest quality and to comply with global regulations. For more information, please visit www.kudobio.com.
Company description
uBriGene Biosciences is your bridge from ATMPs concept to commercialization. Our CDMO+ services include cell therapy products (CAR-T, TCR-T, NK Cells, iPSC, Dendritic cells, Macrophages), viral vectors (AAV, LVV, RVV, AdV, oncolytic viruses), plasmids, and RNA (mRNA, circRNA, acRNA).
Our extensive experience in manufacturing, QC testing, and regulatory filing support of ATMPs, from early discovery to commercialization, will accelerate your therapeutic programs from bench to bedside.
With four Centers of Excellence in North America, and Asia Pacific and more than 20 GMP clean room suites, uBriGene supports global CGT, vaccine, and RNA product development.
Company description
Kudo Biotechnology, Inc (Kudo Bio) is a leading global contract development and manufacturing organization (CDMO), providing world-class, end-to-end mRNA manufacturing solutions all under one roof, as well as commercial fill-finish. Kudo Bio is headquartered in the US and has state-of-the-art facilities including a Process Science Center of Excellence in Needham, Massachusetts, a clinical GMP manufacturing facility and MSAT laboratories in Shanghai, with additional presence in Singapore. Our GMP manufacturing facility spans over 57,000 sqf, designed in accordance with cGMP and global regulatory guidelines, and our production lines cater for preclinical through Phase 3 and commercial. We also offer Fill & Finish, Testing & Release, and Supply Chain Management, and for mRNA and LNP manufacturing we also offer Process and Analytical Development and Technology Transfer. Kudo Bio has a robust quality management system to ensure the highest quality and to comply with global regulations. For more information, please visit www.kudobio.com.
Company description
uBriGene Biosciences is your bridge from ATMPs concept to commercialization. Our CDMO+ services include cell therapy products (CAR-T, TCR-T, NK Cells, iPSC, Dendritic cells, Macrophages), viral vectors (AAV, LVV, RVV, AdV, oncolytic viruses), plasmids, and RNA (mRNA, circRNA, acRNA).
Our extensive experience in manufacturing, QC testing, and regulatory filing support of ATMPs, from early discovery to commercialization, will accelerate your therapeutic programs from bench to bedside.
With four Centers of Excellence in North America, and Asia Pacific and more than 20 GMP clean room suites, uBriGene supports global CGT, vaccine, and RNA product development.
